177 Huntington Ave,
16th Floor Boston, MA 02115
+1 617 830 2100
Dec 1, 2016

Tracelink, Helping The Pharma Industry Trace And Track Drugs, Lands $51.5M From Goldman Sachs

Read the full article here.


TraceLink, the SaaS platform for tracking and tracing pharmaceuticals, has today announced the close of a $51.5 million Series C financing led by Goldman Sachs Growth Equity. Existing investors, such as FirstMark Capital, Volition Capital, and F-Prime Capital, also participated in the round.

As part of the deal, Goldman’s Jason Kreuziger is joining TraceLink’s board of directors.

TraceLink was founded in 2009 with the introduction of the Life Sciences Cloud, a suite of SaaS applications that are natively integrated with AWS. The Life Sciences Cloud allows pharmaceutical businesses to comply with country-specific track and trace requirements throughout their supply chain.

In 2013, the DSCSA (Drug Supply Chain Security Act) was passed, requiring pharmaceutical companies across the supply chain to do a better job of tracking drugs from manufacture to the patient. The Act gives ten years before unit-level traceability is enforced, giving the industry the chance to invest in the services and equipment necessary to achieve compliance.

That’s where TraceLink comes in.

TraceLink’s software allows manufacturers, distributors and dispensers to secure their drug supply chain and stop the trade of counterfeit medicines. According to the company, the issue of counterfeit medicines causes hundreds of thousands of deaths each year and leads to an estimated $75 billion in lost industry revenue annually.

Here’s what TraceLink CEO Shabbir Dahod had to say about it:

Thousands of businesses in the pharmaceutical supply chain need to make decisions on how to comply with time-bound regulations. With limited choices available, TraceLink wants to give these companies the opportunity to meet the regulations and achieve benefits beyond compliance with an established track and trace solution that can help them safely deliver drugs to patients. As a result of this growing industry need, we have continued to surpass our growth goals and are delighted to have this support from world-class, visionary investors to pursue our dedicated strategy in this space and further accelerate the adoption of our proven platform and leadership across the global market.

If you want to learn more about TraceLink, hit up the website right here.

Similar Articles
  • Volition
    Funding Announcement
    Arteza Raises $24m Series A With Volition Capital; Achieves 10x Revenue Growth Over Two Years
    Read Press Release  High growth consumer brand is disrupting the multi-billion dollar art supplies industry by providing well designed and affordable products direct-to-consumer MIAMI (PRWEB) NOVEMBER 26, 2019 Arteza, the leading direct-to-consumer arts and crafts supplies company, today announced it has raised $24 million in Series A funding from growth equity firm Volition Capital. The company’s revenue growth … Continued
    Read more
  • Volition
    Company Updates
    Tracelink Proves Continued Success in Global Customer and Network Growth in Q3 2019
    Read Press Release on PRNewswire NORTH READING, Mass., Nov. 21, 2019 /PRNewswire/ — TraceLink Inc., a network-based platform company with the world’s largest integrated digital supply network, today announced financial and company results for the third quarter of 2019. Financial growth highlights for Q3 2019 include: A 59 percent increase in new year-to-date bookings in the U.S.; … Continued
    Read more